NOVARTIS AG-SPONSORED ADR (NVS) Stock News
NYSE:NVS - New York Stock Exchange, Inc. - US66987V1098 - ADR - Currency: USD
NVS Latest News, Press Relases and Analysis
This Dividend ETF Is Near Its Highest Level Ever -- Is It Too Late to Invest in It?
Trump's 200% tariff threat leaves pharma firms scrambling with scenario planning
A 200% tariff rate — even with a delay — will have a detrimental effect on drug prices and profit margins, analysts warn.
Friday's big stock stories: What's likely to move the market in the next trading session
Both the S&P 500 and the Nasdaq notched fresh all-time closing highs on Thursday, despite steep tariffs for Brazil.
Mentions: SBUX
Here's Why Novartis (NVS) is a Strong Momentum Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Pfizer, Astellas Report Xtandi Survival Win In Prostate Cancer Study
Xtandi plus leuprolide improved overall survival in prostate cancer patients in the Phase 3 EMBARK trial, with no new safety concerns reported.
Mentions: PFE
UBS Maintains a Buy on Genmab (GMAB) With a DKK2,500 PT
Genmab A/S (NASDAQ:GMAB) is one of the 13 Cheap Healthcare Stocks with Huge Upside Potential. On June 25, UBS analyst Xian Deng maintained a Buy rating on Genmab A/S (NASDAQ:GMAB) and set a price target of DKK2,500.00. The company reported $715 million in revenue for the first three months of 2025 compared to $603 million […]
Ascentage Pharma Names CFO & SVP of Global Corporate Development & Finance
By Karen Roman Ascentage Pharma Group International (Nasdaq: AAPG) said it designated Veet Misra, Ph.D., as Chief Financial Officer, and Eric Huang as Senior Vice President of Global Corporate Development and Finance. Dr. Misra has more than 20 years of experience in investment banking as well as a strong scientific background in biology, and he […]
Novartis Wins Approval for First Malaria Treatment for Babies
Novartis AG won regulatory approval for the first medicine designed for babies with malaria, the latest development in the global fight against the mosquito-borne disease.
Novartis Blockbuster Antibody Drug Fails in Late-Stage Trial
Novartis AG’s drug Cosentyx failed in a late-stage study of patients suffering from inflammation in their blood vessels, a blow to the Swiss company’s efforts to find new uses for the blockbuster medicine.
Actinium Highlights ATNM 400 Progress at SNMMI Conference
Actinium Pharmaceuticals, Inc. (NYSE:ATNM) is among the best growth stocks to invest in for the next 5 years. During the Society of Nuclear Medicine & Molecular Imaging annual meeting in New Orleans, Actinium Pharmaceuticals, Inc. (NYSE:ATNM) showcased promising preclinical results for its prostate cancer candidate, ATNM-400. The data indicated that the leading drug demonstrated superior […]
Novartis (NVS) Acquires Regulus Therapeutics for $1.7 Billion
Novartis AG (NYSE:NVS) is one of the 11 best European stocks to invest in. On June 23, the company confirmed it had completed the acquisition of Regulus Therapeutics. Following the acquisition, the shares of Regulus ceased trading on the NASDAQ exchange, and the company became a fully owned subsidiary of Novartis. The acquisition marks a […]
Why New Incyte CEO Bill Meury Is Stoking Investors' M&A Hopes
Bill Meury will take the place of Herve Hoppenot, who is retiring after 11 years at Incyte's helm.
Can Biogen Outdo Its Own Spinal Muscular Atrophy Drug?
Biogen is hoping to top its own spinal muscular atrophy treatment, Spinraza, with a next-generation version.
Ionis (IONS) Announces Leadership Transition as R&D Veteran Richard Geary Prepares to Retire
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) is one of the 10 biotech stocks screaming a buy. On June 12, the company announced the upcoming retirement of Richard Geary, Ph.D., its executive vice president and chief development officer, effective January 2026. Holly Kordasiewicz, Ph.D., currently senior vice president of neurology, will take over the role. Geary has been […]
NYSE Content Advisory: Pre-Market update + Wall Street reopens after Juneteenth
/PRNewswire/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today's NYSE Pre-market...
Mentions: AII